The Medical Affairs Blueprint for Biotech

Medical affairs should be set up early as a core part of the strategy. Engaging late in the game can be a risky mistake.

The whitepaper lays out a practical “medical affairs blueprint” for pre-revenue and early-commercial biotechs to build medical affairs from a blank slate, treating it as a core strategic pillar from the outset rather than a late-stage support function. The authors suggest that where the company’s survival hinges on a single asset, delaying medical affairs is not just outdated but a material strategic liability. Instead, early medical affairs should act as a catalytic, integrative force that elevates value across approval, access, advocacy, and adoption from day one.

Why does the external environment make early medical affairs essential? Scientific and clinical complexity is rising, stakeholders demand differentiated evidence (including real-world and economic value), and commercial access to key stakeholders is increasingly restricted, creating a vacuum for credible, non-promotional scientific exchange. In this setting, success is “earned” through early, stakeholder-specific demonstration of value, not post-launch promotional strength. The paper positions medical affairs as the organization’s scientific conscience and primary conduit for external insight, shaping the asset’s value story early enough to withstand payer, provider, and patient scrutiny.

Discover why these thought leaders organized this blueprint around three imperatives all mapped to “value inflection points” and clinical phases so leaders can scale investment in a capital-efficient way.

• • Early medical affairs engagement can shape approval, access, advocacy, and adoption.
  • Lumanity’s Value Inflection Point framework maps an asset’s journey and highlights where targeted interventions boost success.

• • Across these points, three core imperatives shift medical affairs from a cost center to a value-generating function with lasting impact.

Why Partner with Us?

We know the constraints of biotech because we have lived them, partnering with over 100 biotech businesses to navigate these exact challenges. Our mission is to elevate your medical impact and empower your team to be the catalytic and integrating force that elevates biotech value from day one.

Partner with us to transform your medical affairs function from a blank slate into your most powerful engine for translating science into human impact.